News

Premacure is currently developing a protein replacement therapy to treat retinopathy of prematurity (ROP), a rare and potentially blinding eye disorder that primarily affects premature infants. Based on

Fluvoxamine maleate ER capsules are indicated for the treatment of obsessive compulsive disorder (OCD), which is characterized by recurrent and persistent ideas or images that are recognized by

The Diana system protects clinicians from exposure to hazardous drugs and needlesticks, while protecting the patient preparation from exposure to environmental contaminants. The original version has been in

The contract will focus on the development and commercialization of Ligand’s Captisol-enabled, propylene glycol-free (PG-free) melphalan. According to the agreement, Ligand will earn license fee and is eligible

Under the agreement, the TSB and the Indian Global Innovation and Technology Alliance (GITA), sponsored by the Indian government, support the UK and Indian businesses and academics over

ProspectorRx provides access to pricing data of branded drugs, generics, medical devices and supplies directly from drug companies. Clinical Pharmacology is an electronic drug reference technology that provides

The compounds are related to Sirona’s SGLT2 inhibitor and skin depigmenting agents are protected by the patent. TFChem, a subsidiary of Sirona Biochem, originally filed the patent on

The all-oral combination comprises Presidio’s HCV NS5A inhibitor (PPI-668), Boehringer’s HCV protease inhibitor Faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor (BI207127), with or without ribavirin. The trial

Ascending doses of N6022 will be evaluated in the multi center, double-blind study that is being conducted in collaboration with the Cystic Fibrosis Foundation’s Therapeutics Development Network (TDN).